Preparation, evaluation, and first clinical use of <sup>177</sup>Lu‐labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy
Sudipta Chakraborty, Ashutosh Dash(Bhabha Atomic Research Centre), Ajit Shinto(Kovai Medical Center and Hospital), A. Rajeswari(Bhabha Atomic Research Centre), Koramadai Karuppusamy Kamaleshwaran(Kovai Medical Center and Hospital), Haladhar Dev Sarma(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre), P. Thirumalaisamy(Kovai Medical Center and Hospital)
Cited by 28
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99